Hjem › Tripelnegativ brystkreft › Minnesota › Rochester
Kliniske studier for Tripelnegativ brystkreft i Rochester, MN
11 studier for Tripelnegativ brystkreft søker deltakere på steder i og rundt Rochester (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
PRE-ISPY Phase I/II Oncology Platform Program
RekruttererFase 1/2
- Mayo Clinic Comprehensive Cancer Center, Rochester
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
Rekrutterer
- Mayo Clinic, Rochester
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RekruttererObservasjonsstudie
- Mayo Clinic Rochester, Rochester
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
RekruttererFase 2
- Mayo Clinic, Rochester
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
RekruttererFase 1/2
- Mayo Clinic, Rochester
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RekruttererFase 3
- Mayo Clinic Rochester, Rochester
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RekruttererFase 1
- Mayo Clinic Rochester, Rochester
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RekruttererFase 1/2
- Mayo Clinic - Rochester, Rochester
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
RekruttererFase 1
- Mayo Clinic Rochester, Rochester
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RekruttererFase 2
- Mayo Clinic, Rochester
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RekruttererFase 1/2
- Mayo Clinic, Rochester
Tripelnegativ brystkreft-studier i andre byer
- Houston, TX42 studier
- New York City, NY31 studier
- Nashville, TN28 studier
- Los Angeles, CA27 studier
- Boston, MA26 studier
- San Antonio, TX23 studier
- St. Louis, MO21 studier
- Arlington, VA20 studier
- Atlanta, GA20 studier
- Dallas, TX18 studier
- Chicago, IL16 studier
- Columbus, OH16 studier
Andre studier i Rochester
- Brystkreft42 studier
- Ikke-småcellet lungekreft37 studier
- Metastatisk kreft31 studier
- Kreft (alle typer)30 studier
- Eggstokkreft29 studier
- Kolorektal kreft29 studier
- Multipelt myelom24 studier
- Hjertesvikt22 studier
- Prostatakreft22 studier
- Pankreaskreft22 studier
- Endometriekreft20 studier
- Lungekreft20 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.